- Home
- ESPR
as 07-26-2024 4:00pm EST
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
Upcoming Earnings Alert:
Get ready for potential market movements as Esperion Therapeutics Inc. ESPR prepares to release earnings report on 30 Jul 2024.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | ANN ARBOR |
| Market Cap: | 475.5M | IPO Year: | 2013 |
| Target Price: | $8.83 | AVG Volume (30 days): | 9.0M |
| Analyst Decision: | Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.99 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.70 - $3.40 | Next Earning Date: | 07-30-2024 |
| Revenue: | $229,740,000 | Revenue Growth: | 183.74% |
| Revenue Growth (this year): | 184.42% | Revenue Growth (next year): | 28.68% |
Stock Insider Trading Activity of Esperion Therapeutics Inc. (ESPR)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Foody Joanne M. | ESPR | Chief Medical Officer | Jun 18 '24 | Sell | $2.87 | 3,285 | $9,418.10 | 273,779 | SEC Form 4 |
| Warren Eric | ESPR | Chief Commercial Officer | Jun 18 '24 | Sell | $2.86 | 2,540 | $7,254.24 | 165,586 | SEC Form 4 |
| Warren Eric | ESPR | Chief Commercial Officer | May 17 '24 | Sell | $2.48 | 192 | $476.74 | 168,126 | SEC Form 4 |
Latest Esperion Therapeutics Inc. News
ESPR Breaking Stock News: Dive into ESPR Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Esperion to Report Second Quarter 2024 Financial Results on August 12
GlobeNewswire
3 days ago
Esperion to Participate in Upcoming BTIG Biotech Conference
Zacks
4 days ago
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
GlobeNewswire
11 days ago
New Digital First Marketing Campaign from Esperion Alerts Patients with Uncontrolled LDL Cholesterol to the “Lipid Lurkers” Inside Their Arteries
MT Newswires
a month ago
Esperion Therapeutics Enters $304.7 Million Royalty Purchase Agreement with OMERS; Shares Rise
BioPharma Dive
a month ago
PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar
GlobeNewswire
a month ago
Esperion Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
Zacks
a month ago
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?
Compare ESPR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ESPR Esperion Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.